This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: Teva

Health stocks reflected varied news on the Monday after the July Fourth holiday, from unfavorable trial results, side effects and cost-effectiveness assessments as well analyst notes.

Teva (TEVA) skidded after the company said that according to top-line results of a trial dubbed "FORTE" the higher, 40mg dose of Copaxone was no more effective than the already FDA-approved 20mg dose in relapsing-remitting multiple sclerosis (RRMS).

Teva shares fell $4.54, or 9.6%, to $42.66. The stock is a component of the Amex pharmaceutical index, which was down 5.74, or 1.9%, at 293.79.

Incidentally, the only stock component of the pharmaceutical index that wasn't in the red Monday afternoon was pharma player Wyeth (WYE). Its shares were up 52 cents, or 1.1%, at $47.51. The company said in a release on July 3 (the last regular trading day prior to Monday) that it received European approval to market Relistor subcutaneous injection for pain-killer-induced constipation in patients with advanced illness who are receiving palliative care when typical laxative therapy is insufficient.

One stock bucking downward trends, APP Pharmaceuticals (APPX) rocketed $5.27, or 30%, to $23.09 after German health care company Frenenius said it will buy the Schaumburg, Ill., drugmaker for $3.7 billion, or roughly $23 a share, a 29% premium to APP's closing price on Thursday.

Meanwhile, a medical expert panel that advises European regulators preliminarily concluded that GlaxoSmithKline's (GSK) Tyverb is not a cost-effective treatment for breast cancer. The drug, which has received conditional approval in Europe, has to receive full government approval in order to be available to all patients at subsidized rates. Glaxo shares were down $1.01, or 2.2%, at $45.76.

Also on the decline, Genentech (DNA) gave up $2.43, or 3.1%, to $75.51 on unconfirmed cases of PML, a deadly brain infection, in rheumatoid arthritis patients treated with Rituxan, as mentioned in a Leerink Swann report. PML is listed on the drug's label as a possible side effect.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs